The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine

[1]  A. Engert,et al.  An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  B. Cheson.  Radioimmunotherapy of non-Hodgkin lymphomas. , 2003, Blood.

[3]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Sakamoto,et al.  Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies , 2002, Stem cells.

[5]  L. Polito,et al.  Ribosome-inactivating and Adenine Polynucleotide Glycosylase Activities in Mirabilis jalapa L. Tissues* , 2002, The Journal of Biological Chemistry.

[6]  Yuni Fang,et al.  Binding to CD20 by Anti-B1 Antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines , 2002, Cancer Immunology, Immunotherapy.

[7]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[8]  J. Baars,et al.  Complement activation plays a key role in the side‐effects of rituximab treatment , 2001, British journal of haematology.

[9]  A. López-Guillermo,et al.  Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. , 2001, Blood.

[10]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[11]  A. Bolognesi,et al.  Immunotoxins Containing Recombinant Anti-CTLA-4 Single-Chain Fragment Variable Antibodies and Saporin: In Vitro Results and In Vivo Effects in an Acute Rejection Model1 , 2001, Journal of Immunology.

[12]  D. Goldenberg.  The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. , 2001, Critical reviews in oncology/hematology.

[13]  E. V. Van Damme,et al.  Ribosome‐inactivating proteins from plants: more than RNA N‐glycosidases? , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  S. Johnson,et al.  Nucleoside analogues in the treatment of haematological malignancies , 2001, Expert opinion on pharmacotherapy.

[15]  Malone Dg.  Mechanism of action of rituximab. , 2001 .

[16]  N. Mitsiades,et al.  Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies , 2001, Journal of immunotherapy.

[17]  R. Wiley,et al.  Targeted Toxins , 2001, Current protocols in neuroscience.

[18]  M. Kaminski,et al.  Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. , 2000, Blood.

[19]  L. Polito,et al.  In vitro anti‐tumour activity of anti‐CD80 and anti‐CD86 immunotoxins containing type 1 ribosome‐inactivating proteins , 2000, British journal of haematology.

[20]  M. Gobbi,et al.  Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Fisher,et al.  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. , 2000, Cancer biotherapy & radiopharmaceuticals.

[22]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Kreitman.  Immunotoxins for targeted cancer therapy. , 1998, The AAPS journal.

[24]  Min Wu,et al.  Are immunoconjugates useful for therapy with autoimmune diseases? , 1997, International journal of immunopharmacology.

[25]  L. Barbieri,et al.  Polynucleotide:adenosine glycosidase activity of ribosome-inactivating proteins: effect on DNA, RNA and poly(A). , 1997, Nucleic acids research.

[26]  L. Polito,et al.  Induction of apoptosis by ribosome‐inactivating proteins and related immunotoxins , 1996, International journal of cancer.

[27]  P. Zinzani,et al.  Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells. , 1994, Leukemia & lymphoma.

[28]  L. Barbieri,et al.  Ribosome-inactivating proteins from plants. , 1993, Biochimica et biophysica acta.

[29]  A. Bolognesi,et al.  A comparison of anti‐lymphocyte immunotoxins containing different ribosome‐inactivating proteins and antibodies , 1992, Clinical and experimental immunology.

[30]  M. Gobbi,et al.  In vitro bone marrow purging of multidrug-resistant cells with a mouse monoclonal antibody directed against Mr 170,000 glycoprotein and a saporin-conjugated anti-mouse antibody. , 1990, Cancer research.

[31]  G. Pinkus,et al.  Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. , 1984, Blood.

[32]  R. Schweet,et al.  Synthesis of hemoglobin in a cell-free system. I. Properties of the complete system. , 1962, The Journal of biological chemistry.

[33]  R. Schweet,et al.  THE SYNTHESIS OF HEMOGLOBIN IN A CELL-FREE SYSTEM. , 1958, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Barbieri,et al.  An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells , 2004, Cancer Immunology, Immunotherapy.

[35]  D. Scheinberg,et al.  Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies , 2002, Leukemia.

[36]  D. Maloney.  Mechanism of action of rituximab. , 2001, Anti-cancer drugs.

[37]  A. Bolognesi,et al.  An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins. , 1999, Haematologica.

[38]  A. Tedeschi,et al.  Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  E. Vitetta,et al.  Immunotoxins: an update. , 1996, Annual review of immunology.

[40]  L. Barbieri,et al.  Large scale chromatographic purification of ribosome-in-activating proteins , 1987 .

[41]  Yuni Fang,et al.  Binding to CD 20 by Anti-B 1 Antibody or F ( ab ’ ) 2 is sufficient for induction of apoptosis in B-cell lines , 2022 .